Finally, our work identifies the ruthenium-based plecstatin-1 (PST), as a candidate drug that can mimic the genetic ablation of plectin, thus providing a robust preclinical proof-of-concept for PST in the treatment of HCC. This evidence concerns the gene PLEC and hepatocellular carcinoma.